A New Era in Hearing Loss Protection For Cancer Patients

David Freyer, DO
Published Online: May 4, 2017

David Freyer, DO, of the Children's Hospital of Los Angeles praises the clinical trial he was involved with showing that the administration of sodium thiosulfate (STS) in pediatric cancer patients receiving cisplatin reduced the number of patients developing hearing loss. 
This landmark trial was the first of its kind and Dr Freyer is looking forward to future studies in this field to provide options for patients, especially pediatric patients, undergoing platinum-based cancer therapy. 


Freyer DR, Chen L, Krailo MD, et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18:63-74. doi: 10.1016/S1470-2045(16)30625-8

Latest Articles
Dr Michael Davidson of the University of Chicago School of Medicine discusses why a proper diagnosis is so valuable to FCS patients.
CRPS is often difficult to diagnose and in Jones’ case, that was also true. His symptoms appeared suddenly while playing high school football.
At the 2017 NLA Sessions, Rare Disease Report sat with dietician Wahida Karmally from Columbia University to discuss the necessary diet for FCS patients.
Michael Weschler, MD presents data at the 2017 American Thoracic Society Conference that shows the FDA-approved mepolizumab helps in the treatment of EGPA.
$vacMongoViewPlus$ $vAR$